Viral keratitis-inhibitory effect of 9-beta-D-arabinofuranosylhypoxanthine 5'-monophosphate.
Topical application of 9-beta-d-arabinofuranosylhypoxanthine 5'-monophosphate (ara-HxMP) significantly inhibited the development of keratitis induced by types 1 and 2 herpes simplex virus and vaccinia virus in the eyes of rabbits. Parameters for evaluation of efficacy were infectivity (corneal opacity, lesion size, and type), Draize (erythema, conjunctival swelling, and discharge), and reduction in titer of recoverable virus from the eye. When the relative efficacy of the related compounds 9-beta-d-arabinofuranosyladenine (ara-A), ara-A 5'-monophosphate (ara-AMP), and ara-Hx was determined against type 1 herpes simplex virus in a parallel experiment, the more water-soluble compounds (ara-HxMP, ara-AMP) were the most effective. The relative efficacy of ara-A was also determined against type 2 herpes and vaccinia virus-induced keratitis. Mortality in rabbits due to central nervous system involvement caused by types 1 and 2 herpes simplex virus was inhibited. Ara-HxMP was not discernibly toxic to the eye at concentrations of at least 20%; efficacy was still discernible with a 0.1% solution.
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001089:Arabinose / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D007291:Inosine Monophosphate / Q000627:therapeutic use*; D007292:Inosine Nucleotides / Q000627:therapeutic use*; D007634:Keratitis / Q000188:drug therapy*; D007635:Keratitis, Dendritic / Q000188:drug therapy; D011817:Rabbits; D013997:Time Factors; D014615:Vaccinia / Q000188:drug therapy; D014740:Vidarabine / Q000627:therapeutic use
D000998:Antiviral Agents; D007292:Inosine Nucleotides; D007291:Inosine Monophosphate; D001089:Arabinose; D014740:Vidarabine